Neurogene Inc. — Director's Dealing 2014

Mar 14, 2014

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AQUINOX PHARMACEUTICALS, INC (AQXP)
CIK: 0001404644
Period of Report: 2014-03-12

Reporting Person: PFIZER INC (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2014-03-12	Common Stock	C	962603	—	Acquired	962603	Direct
2014-03-12	Common Stock	P	272727	$11.00	Acquired	1235330	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2014-03-12	Series B-1 Preferred Stock	$	C	334420	Disposed		Common Stock (334420)	Direct
2014-03-12	Series B-2 Preferred Stock	$	C	327178	Disposed		Common Stock (327178)	Direct
2014-03-12	Series C Preferred Stock	$	C	301005	Disposed		Common Stock (301005)	Direct

Footnotes

F1: Each share of the issuer's Series A-1, Series A-2, Series B-1, Series B-2 and Series C Preferred Stock converted into Common Stock of the issuer on a 1-to-1 basis upon the closing of the issuer's initial public offering, and has no expiration date.